多西他赛联合顺铂同步放化疗治疗局部晚期食管癌的疗效分析

目的研究多西他赛联合顺铂化疗同步三维适形放射治疗(3D-CRT)治疗局部晚期食管癌的近期疗效及毒副反应。方法将68名经病理确诊的食管癌局部晚期患者随机分为DP治疗组33例和PF治疗组35例。DP治疗组采用多西他赛联合顺铂,PF治疗组采用5-氟尿嘧啶联合顺铂,两组均采用3D-CRT计划,照射剂量为56～60Gy,2Gy/次,5次/周。结果 DP治疗组的总反应率为90.9%,PF治疗组的总反应率为82.9%;DP治疗组1、2年的总生存率分别为81.8%和48.5%;PF治疗组1、2年的总生存率分别为74.3%和37.1%;差异有统计学意义(P<0.05)。结论多西他赛联合顺铂化疗同步三维适形放射治疗治疗局部晚期食管癌近期疗效较好,但是还需要进行长期的随访观察。

Clinical analysis of efficacy in docetaxel plus cisplatin chemotherapy with 3D-CRT in treatment of advanced esophageal cancer

Objective To evaluate the efficacy of docetaxel plus cisplatin chemotherapy with concurrent three dimensional radiotherapy in patients with locally advanced esophageal cancer.Methods A total of 68 patients with locally advanced esophageal cancer were divided randomly into the DP group with 33 cases and the PF group with 35 cases.The patients in the DP group were treated with docetaxel and cisplatin.The patients in the PF group were treated with 5-FU and cisplatin.Both groups received 3-DCRT radiotherapy with a total dose of 56-60Gy,2Gy/F,5 times per week.Results The overall response(CR+PR) rate was 90.9% in the DP group and 82.9% in the PF group(P<0.05).The one and two year survival rate in DP group were 81.8% and 48.5% and PF group was 74.3% and 37.1% respectively,with a statistical significance(P<0.05).Conclusion 3-DCRT combined with concurrent docetaxel plus cisplatin chemotherapy can effectively treat advanced esophageal cancer.However,further study is needed for longer-term curative effect of the regimen,which should involve more patients and a prolonged follow-up.